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Abstract
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease caused by loss of
motor neurons. ALS patients experience rapid deterioration in muscle function with an aver-
age lifespan of 3–5 years after diagnosis. Currently, the most effective therapeutic only
extends lifespan by a few months, thus highlighting the need for new and improved thera-
pies. Neurotrophic factors (NTFs) are important for neuronal development, maintenance,
and survival. NTF treatment has previously shown efficacy in pre-clinical ALS models.
However, clinical trials using NTFs produced no major improvements in ALS patients, due
in part to the limited blood brain barrier (BBB) penetration. In this study we assessed the
potential neuroprotective effects of a novel class of compounds known as MicroNeurotro-
phins (MNTs). MNTs are derivatives of Dehydroepiandrosterone (DHEA), an endogenous
neurosteroid that can cross the BBB and bind to tyrosine kinase receptors mimicking the
pro-survival effects of NTFs. Here we sought to determine whether MNTs were neuropro-
tective in two different models of ALS. Our results demonstrate that BNN27 (10 μM) attenu-
ated loss of motor neurons co-cultured with astrocytes derived from human ALS patients
with SOD1 mutations via the reduction of oxidative stress. Additionally, in the G93A SOD1
mouse, BNN27 (10 mg/kg) treatment attenuated motor behavioral impairment in the paw
grip endurance and rotarod tasks at postnatal day 95 in female but not male mice. In con-
trast, BNN27 (10 mg/kg and 50 mg/kg) treatment did not alter any other behavioral outcome
or neuropathological marker in male or female mice. Lastly, BNN27 was not detected in
post-mortem brain or spinal cord tissue of treated mice due to the rapid metabolism of
BNN27 by mouse hepatocytes relative to human hepatocytes. Together, these findings
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demonstrate that BNN27 treatment failed to yield significant neuroprotective effects in the
G93A SOD1 model likely due to its rapid rate of metabolism in mice.
Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by the
loss of motor neurons in the cortex, brainstem, and spinal cord. The average age of onset is 50–
75 years [1] with patients initially reporting symptoms that include muscle twitching, upper
and lower limb weakness, or difficulty swallowing or breathing [1, 2]. ALS patients experience
rapid deterioration in muscle function resulting in an average lifespan of 3–5 years following
symptom onset [2, 3]. Currently the only disease-modifyingtherapeutic for ALS, Riluzole, pro-
duces modest symptomatic effects prolonging survival by just 3–6 months [4–6], highlighting
the critical need for the development of novel therapies that slow or prevent disease
progression.
Neurotrophic factors (NTFs) are a class of proteins important for cell differentiation, neuronal
growth, and neuronal survival [7]. NTFs include nerve growth factor (NGF), brain-derived neu-
rotrophic factor (BDNF) and neurotrophin 3 (NT3) and 4 (NT4), each of which bind to specific
subtypes of pro-survival tyrosine receptor kinases (Trks) as well as p75 neurotrophin receptors
[7]. In addition, other growth factors, such as ciliary neurotrophic factor (CNTF) and glial-cell
derived neurotrophic factor (GDNF), also produce similar actions in the central nervous system
(CNS) [7]. Reduced levels of NTFs have been reported in several neurodegenerative disorders
[8], including ALS [9–11], suggesting that loss of trophic support could be important in disease
pathophysiology. Additionally, previous studies in ALSmousemodels demonstrated preclinical
efficacyusing BDNF, CNTF, and GDNF [12–22]. As a result, the therapeutic effects of several
NTFs were tested in clinical trials for ALS as well as other neurodegenerative disorders [23–26].
Despite the promising preclinical results in ALSmodels, NTFs have yet to meet their potential as
therapies for the treatment of ALS as they did not demonstrate efficacy in clinical trials [27–30].
Onemajor issue with NTF clinical trials was delivery to the CNS. Subsequent studies demon-
strated that most NTFs do not readily cross the blood-brain barrier (BBB) [31–34], highlighting
a major obstacle underlying the lack of efficacy in NTF clinical trials [35].
Dehydroepiandrosterone (DHEA) is an endogenous neurosteroid produced in both neu-
rons and glia [36, 37] that can also cross the BBB [38]. DHEA, which normally declines with
age [39], has been shown to exert neuroprotective effects in several experimentalmodels [40–
44]. DHEA is known to alter the activity of γ aminobutiric acid type A (GABAA), N-methyl-D-
aspartate (NMDA), sigma1, estrogen and androgen receptors at micromolar concentrations
[39]. More recent in vitro findings demonstrated that DHEA also activates NGF receptors,
tyrosine receptor kinase A (TrkA) and p75 neurotrophin receptors, at nanomolar concentra-
tions inducing phosphorylation of TrkA and activation of downstream signaling proteins [45].
Moreover, DHEA treatment attenuated apoptosis in dorsal root ganglia sensory neurons
derived fromNGF null mice [45] suggesting a neuroprotective role. Based on the promising
effects of DHEA, 17-spiro derivatives of DHEA, known as microneurotrophins (MNTs), were
synthesized [46]. Similar to DHEA, MNTs exhibit anti-apoptotic effects in vitro [46]. While
nanomolar concentrations of MNTs bind to and activate TrkA and p75 receptors ([47], Pedia-
ditakis et al., unpublished data), these lower concentrations do not activate steroid hormone
receptors [46], thus avoiding the potential estrogenic or androgenic effects of DHEA [39].
Given the neuroprotective effects of DHEA and the structural and functional similarities
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betweenDHEA and MNTs, we sought to examine whether the MNTs were neuroprotective in
two different models of ALS. First, we measured the effects of MNTs on mouse motor neurons
co-culturedwith astrocytes derived from human ALS patients with SOD1 mutations. Next, we
assessed alterations in body weight, neurological score, motor deficits, and survival in the
SOD1 G93Amouse model following treatment with the MNT BNN27. Additionally, neuro-
pathologicalmarkers, including lower motor neuron counts in the lumbar spinal cord and
quantification of neuromuscular junction (NMJ) integrity in the tibialis anterior muscle, were
also assessed following BNN27 treatment.
Materials and Methods
MicroNeurotrophin compounds
BNN20, 23 and 27 were characterized previously [46]. Briefly, these were spiro-epoxy deriva-
tives of dehydro-epiandrosterone (DHEA) obtained via modifications at C-17; BNN20: (17β-
spiro[5-androstene-17, 20-oxiran]-3β-ol, BNN23: (20S)-3β,21-dihydroxy-17β,20-epoxy-
5-pregnene, and BNN27: (20R)-3β,21-dihydroxy- 17R,20-epoxy-5-pregnene. BNN20 is a sim-
ple 17,20-spiro epoxy DHEA analogue. BNN23 and BNN27 possess a C21-hydroxyl group,
which can participate in hydrogen bond formation with putative molecular targets and thus
enhance specific binding capacity to putative receptors. Additionally, BNN23 and BNN27 dif-
fer in the stereochemistry of their epoxide ring (BNN23: (20S)-3,21-dihydroxy-17,20-epoxy-
5-pregnene, BNN27: (20R)-3,21-dihydroxy-17r,20-epoxy-5-pregnene). Additional informa-
tion in regards to the synthesis of MNTs can be found in [46].
ES Motor Neuron Differentiation
Mouse embryonic stem cells expressing GFP under the motor neuron (MN)-specific promoter
HB9 (HBG3 cells; gift from Tom Jessell) were cultured on primarymouse embryonic fibro-
blasts (Millipore). For differentiation into MNs, cells were treated with trypsin and resus-
pended in DFK10 culture medium consisting of knockout DMEM/F12, 10% knockout serum
replacement, 1% N2, 0.5% L-glutamine, 0.5% glucose (30% in water), and 0.0016% 2-mercap-
toethanol. The cells were plated on non-adherent Petri dishes to allow formation of embryoid
bodies. After 1 d of recovery, 2μM retinoic acid (Sigma) and 1μM SmoothenedAgonist (SAG)
(Millipore) were added to the medium every day for 5 days. Embryoid bodies were then disso-
ciated with papain and sorted using the FACSAria™ III (BD Biosciences).
Human fibroblasts and co-cultures
Human skin fibroblast samples from 3 unaffected controls and 2 patients with SOD1 muta-
tions (Table 1) were obtained from Prof. Pamela Shaw (University of Sheffield, Sheffield,
United Kingdom). Informed written consent was obtained from all subjects before sample col-
lection. These experiments were approved by the Yorkshire & the Humber Research Ethics
Committee (study number STH16573). Fibroblasts were reprogrammed to induced neural pro-
genitor cells (iNPCs) and then differentiated into iAstrocytes as previously described [48].
iAstrocytes were cultured in DMEMGlutamax (Gibco) with 10% FBS (Sigma) and 0.02%
N2 (Invitrogen). On day 0, 10,000 iAstrocytes were seeded in a 96-well plate, on day 1 they
were treated with BNN20, 27 and 23 and Riluzole at increasing concentrations of 1, 10 and
30 μM. On day 2, astrocytemediumwas removed, cells were washed once with PBS and 10,000
Hb9-GFP+ motor neurons were seededonto the astrocytemonolayer in motor neuron medium
(DMEM/F12, 2% knockout serum replacement (Invitrogen), 2% N2, and 2%B27 plus GDNF
(Invitrogen; 10 ng/mL), BDNF (Invitrogen; 10 ng/mL), CNTF (Invitrogen; 10 ng/mL))
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supplemented with the corresponding concentration of drug. Starting from day 3, each well
was scanned using the high content live-imaging system (InCell Bioanalyser) to monitor neu-
ronal survival and axonal growth daily. 9 fields of view at 10x were acquired per well, so that
the area scanned covered the entire well. Each condition was repeated in duplicate and each
experiment was repeated four times. Data analysis was performedwith the InCell Developer
software programmed to count only cell bodies with at least one projection (axon), thus
guaranteeing that only actual cells and not debris were counted in the experiment.
For the CellRox Assay, iAstrocytes were assayed one day following BNN27 (10 μM) treat-
ment. iAstrocytemonocultures (with or without BNN27) were exposed to CellROX1 Orange
(Invitrogen), which detects and quantifies reactive oxygen species (ROS) in live cells. In a
reduced state, the reagent is cell-permeant and non-fluorescent, but upon oxidation the reagent
exhibits strong fluorescence and remains localizedwithin the cell. 30 minutes after applying
CellROX, the plate was washed 3 times to eliminate background signal and images were
acquired using the InCell system (9 fields per well to cover the whole well). Fluorescence quan-
tificationwas performed using ImageJ.
Animals
All animal care, husbandry and experimentationwere performed according to the guidelines set
by theMassachusetts General Hospital Subcommittee on Research Animal Care. These experi-
ments were approved by the Massachusetts General Hospital Institutional Animal Care and Use
Committee (2014N000018). Mice were assessed regularly for motor impairment and euthanized
upon onset of major paralysis (see “Weight and Neurological Scoring” section) to minimize suf-
fering. All mice were given access to food and water ad libitum. B6SJL-Tg(SOD1G93A)1Gur/J
male mice [49] were obtained from Jackson Laboratory and bred with C57Bl6 female mice to
obtain wild-type (Wt) and mutant transgenic (Tg) G93A SOD1-expressing mice. To determine
mouse genotype, DNA extractionwas performed from tail biopsies acquired at postnatal day 28–
40 followed by quantitative real-time PCR (qRT-PCR) using primers for the mutant G93A
SOD1 gene (GGGAAGCTGTTGTCCCAAGand CAAGGGGAGGTAAAAGAGAGC).
Pellet Implantation
Slow-release 90 d pellets (Innovative Research of America, Inc; Sarasota, Florida) were
implanted subcutaneously in the back of mice at postnatal day 55–60. Pellets contained either
placebo or BNN27 at 10 mg/kg or 50 mg/kg. Dosing was determined for an average sizedmale
(Wt: 28.5g, Tg: 25.6g) and female (Wt: 23.0g, Tg: 20.0g) mouse.
Behavior
For all behavioral assessments, the data were collected and analyzed by an investigator who
was blind to the experimental treatment condition.
Table 1.
Sample number Age of onset Age at Biopsy Sex Mutation
91 60 60 M SOD1 I113T
210 37 42 M SOD1 D76Y
Control 155 - 40 M -
Control 3050 - 65 M -
Control 170 - 63 M -
doi:10.1371/journal.pone.0164103.t001
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Gait analysis. Manual gait analysis was performed using a limb painting procedure similar
to previous studies [50, 51]. Mice were first trained to traverse a horizontal corridor leading
directly into their home cage by gentle nudges in the appropriate direction if they stopped or
attempted to turn around. After pellet implantation, the bottoms of their hindlimbs were
painted, by brushing with non-toxic food dye (Fisher Scientific), and the mice were allowed to
walk the path to their home cage on a piece of paper. Three trials were performed at each
experimental time point (p55, p75, p95, p115, p135). Stride length and width was determined
by measuring the distance between the same points, on the ball mount region of the footprint,
in two consecutive footprints. Stride length and width was calculated from 2–3 hindpaw strides
when the animal was walking continuously at a constant pace. Steps just before the entry to the
home cage were not included since mice often slowed down and made smaller steps at this
point. Mean data from 4–6 strides across three trials was calculated.
Rotarod. Mice were placed on a fixed speed (16 rpm) rotating rod (3.0cm) (Rotamex,
Columbus Instruments) [52, 53]. Prior to pellet implantation, mice were trained to remain
on the rotarod for 180 seconds. For each experimental time point (p55, p95, p115), the time
mice spent on the rotating rod was calculated up to a maximum of 180 seconds. Three trials
were performed for each time point and the greatest value for each session was used for
analysis.
Paw grip endurance test (PaGE). The PaGE test was performed according to previous
studies [53–55]. Briefly, mice were placed on the wire lid of a conventional housing cage that
was inverted and held at ~45 cm above an open cage bottom. Prior to pellet implantation, mice
were trained to stay on the inverted grid for 90 seconds. For experimental time points (p55,
p75, p95, p115, p135), the time spent on the grid (before falling) was noted up to a maximum
value of 90 seconds. The largest value from three individual trials was used for analysis.
Weight and neurological scoring. Beginning at p55, weight and neurological score (using
the ALS TDI criteria) [56, 57] were recorded for each mouse every 5 days until death or eutha-
nasia. ALS TDI criteria are as follows:
Score of 0: Full extension of hind legs away from lateral midline whenmouse is suspended by
its tail, and mouse can hold this for two seconds, suspended two to three times.
Score of 1: Collapse or partial collapse of leg extension towards lateral midline (weakness) or
trembling of hind legs during tail suspension.
Score of 2: Toes curl under at least twice during walking of 12 inches, or any part of foot is
dragging along cage bottom/table.
Score of 3: Rigid paralysis or minimal joint movement, foot not being used for generating for-
ward motion.
Score of 4: Mouse cannot right itself within 15 seconds after being placed on either side.
Mice were euthanized upon obtaining a score of 4.
Tissue Dissection
Tissue was dissected from Tg G93A SOD1mice upon reaching a neurological score of 4 [56,
57] or following death (if mice died naturally prior to that point). Mice were sacrificedby
administration of slow flow CO2 (10–30% of the chamber volume/minute) followed by imme-
diate decapitation. Brain, gastrocnemius, and tibialis anterior tissue were removed and frozen
in dry ice. Spinal cord was removed, frozen by gently lowering into the gas byproduct of liquid
nitrogen, and dissected into lumbar and non-lumbar regions. All tissue was stored at -80°C
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prior to use. In addition, tail samples were extracted to perform a second round of confirma-
tory qRT-PCR for mouse genotyping. Tail samples were stored at -20°C until used.
Motor neuron quantification
Longitudinal sections (10μm) of the lumbar spinal cord were made from fresh frozen tissue.
Hematoxylin and eosin (H&E) staining was performed on the tissue sections.Within the
region containing the ventral horn, three sections were counted (each separated by 20–30μm)
to cover the areas of highest motor neuron density within the ventral horn. Motor neurons
were identified based on their large size (15μm) and by the presence of at least one nucleolus.
Images were acquired using a Zeiss microscope 20x objective (0.8NA) and processed with
Metamorph image analysis software (Molecular Devices).
Neuromuscular junction quantification
Tissue sectioning, staining, and analysis were performed by Clarapath, Inc (New York, NY).
Briefly, longitudinal sections (20μm) of tibialis anterior muscle were made from fresh frozen
tissue. One to three sections for each specimenwere stained with primary rabbit anti-VACHT
(1:10,000; Covance) and secondaryAlexa Fluor 488 donkey anti-rabbit (1:500; Life Technolo-
gies) antibodies along with a tetramethylrhodamine (TMR) conjugated to α-bungarotoxin
(1:750, Life Technologies). Sections were imaged with a 20x objective (0.75NA, 0.45 μm/pixel
resolution) and analyzed by in-house software to determine the total number of VACHT and
TMR-α-bungarotoxin counts per muscle along with the percent VACHT/TMR-α-bungaro -
toxin per sample area.
Mass Spectrometry
Analysis of MNT levels in tissue samples was carried out by Cyprotex (Watertown, MA). Brain
and spinal cord samples were homogenized in PBS (2 ml per gram of tissue) and homogenates
were crashed with 3 volumes of methanol containing an analytical internal standard (diclofe-
nac). Samples were then centrifuged to remove the precipitated protein and supernatant was
analyzed by LC-MS/MS. All brain and spinal cord samples were compared to a calibration
curve prepared in mouse blank brain and spinal cord homogenates, respectively. Samples were
analyzed by LC-MS/MS using a SCIEXQTrap 5500 mass spectrometer coupled with an Agi-
lent 1290 HPLC Infinity series, a CTC PAL chilled autosampler, both of which were controlled
by Analyst software. After separation on a C18 reverse phase HPLC column (Acquity UPLC
HSS T3, 1.8, 2.1 x 50 mm) using an acetonitrile-water gradient system, peaks were analyzed by
mass spectrometry (MS) using ESI ionization in MRMmode. A quadratic fit calibration curve
was used, with a 1/X2 weighting factor applied to the data points. Open symbols were outside
of the calibration range and not used in the calculations.
Statistics
For the in vitro iAstroctye-mouseMN co-culture experiments, bar charts are used for graphical
representation of the data with the central line representing the mean and the error bar repre-
senting the standard error of the mean (SEM). Comparisons were performedusing an unpaired
t-test or a one-way ANOVA followed by Tukey’s post-tests at a significance level (α) of 0.05.
For the in vivomouse studies, male and female mice were analyzed separately due to their
differing body weights and disease onset [58, 59]. Normal distributions of data were not
assumed regardless of sample size or variance. Data in the main text are presented as median
values. Box plots are used for graphical representation of population data with the central line
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representing the median, the edges representing the interquartile ranges, and the whiskers rep-
resenting 10–90th percentiles. Data are also represented as medians ± interquartile ranges or
percent values. Sample sizes are included in the figure legends for clarity purpose. Comparisons
for unrelated samples were performed using a Mann-Whitney U test or a Kruskal-Wallis test
followed by Dunn’s multiple comparison post-tests at a significance level (α) of 0.05. For
p<0.05 and>0.00001, exact P values (two-tailed) are reported.
Results
To determine whichMNT to test in a mouse model of ALS, we assessed the effects of 3 MNTs,
BNN20, BNN27, and BNN23 (at 1, 10 and 30 μM), in human astrocytes (iAstrocytes) derived
from ALS patients with SOD1 mutations co-culturedwith mouse motor neurons (MNs) in
vitro. In agreement with previous findings [48, 60], MN survival was significantly decreased
in co-cultures with iAstrocytes from a SOD1 patient compared to those from control patients
(t(4) = 20.23, p<0.0001, unpaired t-test) (Fig 1A). There was an overall effect of MNT treat-
ment onMN survivalwhen co-culturedwith SOD1 iAstrocytes (F(9,20) = 0.715, p<0.0001, One-
way ANOVA). BNN27 (10 μM) significantly attenuated the motor neuron loss seen in untreated
SOD1 iAstrocytes as shown by an increase inMNGFP signal (BNN20- 10 μM: 77.84%, SOD1
untreated: 47.60%; p<0.001, Tukey’s test) (Fig 1A). In addition, BNN20 (10 μM) also attenuated
the motor neuron loss seen in untreated SOD1 iAstrocytes (BNN20- 10 μM: 67.76%, SOD1
untreated: 47.60%, p<0.01, Tukey’s test) (Fig 1A).
Since BNN27 (10 μM) yielded the greatest effect on MN survival, we further tested its neu-
roprotective effects in iAstrocytes derived from two individual ALS patients harboring different
SOD1 mutations (SOD1 91 and SOD1 210) (Table 1) along with Riluzole (10 μM), a com-
monly used ALS therapeutic. Similar to the previous experiments, there was an overall effect of
drug treatment on MN survival when co-culturedwith SOD1 iAstrocytes (F(6,21) = 2.013,
p<0.0001, One-way ANOVA). Specifically, BNN27 (10 μM) treatment yielded a significant
increase in MN survival in SOD1 iAstrocytes (SOD1 91- treated: 68.28%, SOD1 91- untreated:
40.22%, p<0.0001, Tukey’s test; SOD1 210- treated: 78.34%, SOD1 210- untreated: 48.13%,
p<0.0001, Tukey’s test) similar to the effects of Riluzole (10 μM) treatment (SOD1 91- Rilu-
zole: 77.58%, SOD1 91- untreated: 40.22%, p<0.0001, Tukey’s test; SOD1 210- Riluzole:
93.23%, SOD1 210- untreated: 48.13%, p<0.0001, Tukey’s test) (Fig 1B).
To determine the mechanism of action for BNN27’s neuroprotective effects onMN survival,
we assessed oxidative stress levels in iAstrocytes from 2 control patients and 2 SOD1 patients
with and without BNN27 treatment. BNN27 treatment in SOD1 iAstrocytes yielded a trend
towards a decrease in phospho-p65 (data not shown), the active subunit of NF-κB that medi-
ates inflammatory [61] and oxidative stress [62] pathways. In agreement with these findings,
BNN27 treatment yielded an overall effect on oxidative stress in iAstrocytes (F(2,9) = 0.853,
p<0.0001, One-way ANOVA) in the CellRox Assay. Specifically, BNN27 treatment signifi-
cantly decreased reactive oxygen species in SOD1 iAstrocytes (BNN27: 742.5 pixels/cell, SOD1
untreated: 568.3 pixels/cell, p<0.001, Tukey’s test), as indicated by a reduction in fluorescent
intensity (Fig 1C).
Given the increased survival of MNs co-culturedwith human SOD1 iAstrocytes, following
MNT treatment, we next tested the potential neuroprotective effects of BNN27 in the G93A
SOD1mouse model. Both age- and litter-matched wild-type (Wt) and transgenic (Tg; G93A
SOD1) male and female mice were implanted subcutaneously with slow release (90 d) pellets
(Innovative Research of America, FL) containing BNN27 (10 mg/kg or 50 mg/kg) or placebo.
Following pellet implantation alterations in motor behavior outcomes as well as neuropatho-
logical markers of disease were assessed.
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Fig 1. MNTs attenuated survival of mouse motor neurons co-cultured with human astrocytes from
SOD1 ALS patients. a) Survival of mouse motor neurons (MNs), expressing GFP under the Hb9 promoter,
was significantly decreased in co-cultures with human astrocytes (iAstrocytes) from an ALS patient a SOD1
mutation (Patient 2/SOD1 210; light grey) compared to those from 3 compiled control patients (3 compiled;
white) (p<0.0001, unpaired t-test). BNN20, BNN27, and BNN23 were each tested at 1 μM (dark grey), 10 μM
(black), and 30 μM (medium grey) in iAstrocyte-mouse MN co-cultures. At 10 μM, BNN20 (p<0.01, Tukey’s
test) and BNN27 (p<0.001, Tukey’s test) significantly increased the survival of MNs co-cultured with SOD1
iAstrocytes relative to untreated samples. b) The effects of BNN27 (red) were tested, along with Riluzole
(dark grey), on iAstrocytes from 3 control patients (compiled) and 2 individual ALS patients each carrying a
distinct SOD1 mutation (Patient 1/SOD1 91 and Patient 2/SOD1 210). Left, BNN27 (10 μM) treatment
yielded a significant increase in MN survival in co-cultures with iAstrocytes from Patient 1 (p<0.0001, Tukey’s
test) and Patient 2 (p<0.0001, Tukey’s test) relative to untreated co-cultures (light grey). Similarly, Riluzole
(10 μM) treatment also significantly increased MN survival in co-cultures with Patient 1 (p<0.0001, Tukey’s
test) and Patient 2 (p<0.0001, Tukey’s test) iAstroctyes. Right, representative images of mouse MNs co-
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First, we determined the effects of BNN27 treatment on body weight and neurological score
(seeMaterials and Methods) [56, 57] in SOD1 mice. As reported previously [52, 53, 63–66], Tg
vehicle-treatedmice exhibited a decrease in weight gain (data presented as a percent of base-
line) at p105 (Tg-vehicle: 111.80%,Wt-vehicle: 123.50%; p = 0.0188, Mann-Whitney U test),
p115 (Tg-vehicle: 110.00%,Wt-vehicle: 124.80%; p = 0.0025, Mann-Whitney U test), p125
(Tg-vehicle: 105.90%,Wt-vehicle: 124.30%; p<0.0001, Mann-Whitney U test), p135 (Tg-vehi-
cle: 100.00%,Wt-vehicle: 126.80%; p<0.0001, Mann-Whitney U test), and p145 (Tg-vehicle:
100.00%,Wt-vehicle: 134.80%; p<0.0001, Mann-Whitney U test) compared to Wt vehicle-
treated mice (Fig 2A; left panel). However, BNN27 treatment (10 mg/kg and 50 mg/kg) had no
effect on body weight (p>0.05, Kruskal-Wallis test) in Tg mice at any time point tested (Fig
2A; right panel). In addition, Tg vehicle-treated mice exhibited significantmotor impairment
as indicated by an increase in neurological score [56, 57] at p95 (Tg-vehicle: 1, Wt-vehicle: 0;
p = 0.0003, Mann-Whitney U test), p105 (Tg-vehicle: 1, Wt-vehicle: 0; p = 0.0036, Mann-Whit-
neyU test), p115 (Tg-vehicle: 1, Wt-vehicle: 0; p = 0.0012, Mann-Whitney U test), p125 (Tg-
vehicle: 1, Wt-vehicle: 0; p<0.0001, Mann-Whitney U test), p135 (Tg-vehicle: 2, Wt-vehicle: 0;
p<0.0001, Mann-Whitney U test), and p145 (Tg-vehicle: 3, Wt-vehicle: 0; p<0.0001, Mann-
WhitneyU test) compared to Wt vehicle-treatedmice (Fig 2B; left panel). Similar to the body
weight analysis, BNN27 treatment (10 mg/kg and 50 mg/kg doses) had no effect on neurologi-
cal score (p>0.05, Kruskal-Wallis test) in Tg mice (Fig 2B; right panel).
Alterations in muscle strength were assessed following BNN27 or vehicle treatment using the
paw grip endurance (PaGE) task. In agreement with previous reports [53, 63, 67], vehicle-treated
Tgmale mice exhibited deficits in the PaGE task as indicated by decreased time spent on the grid
relative toWt vehicle-treatedmale mice at p95 (Tg-vehicle: 41.8 sec,Wt-vehicle: 90.0 sec;
p = 0.0023, Mann-WhitneyU test), p115 (Tg-vehicle: 7.4 sec,Wt-vehicle: 90.0 sec; p = 0.0003,
Mann-WhitneyU test), and p135 (Tg-vehicle: 1.1 sec,Wt-vehicle: 90.0 sec; p = 0.0385, Mann-
WhitneyU test) (Fig 3A; left panel). There was no change in performance in the PaGE task fol-
lowing BNN27 treatment (10 mg/kg or 50 mg/kg) compared to vehicle treatment (p>0.05, Krus-
kal-Wallis test) at any time point tested (Fig 3A; right panel). Similar to males, Tg vehicle-treated
females exhibited deficits in the PaGE task as indicated by decreased time spent on the grid rela-
tive toWt vehicle-treated females at p95 (Tg-vehicle: 69.7 sec,WT-vehicle: 90.0 sec; p = 0.0128,
Mann-WhitneyU test), p115 (Tg-vehicle: 27.2 sec,Wt-vehicle: 90.0 sec; p<0.0001, Mann-Whit-
neyU test), and p135 (Tg-vehicle: 1.2 sec,Wt-vehicle: 90.0 sec; p<0.0001, Mann-WhitneyU
test) (Fig 3C; left panel). In contrast to males, BNN27 treatment yielded an overall effect in
females at p95 in the PaGE task (p = 0.0063, Kruskal-Wallis test). Specifically, BNN27 10 mg/kg
treatment increased the time spent in the PaGE task (Tg-10mg/kg: 90.0 sec, Tg-vehicle: 69.7 sec;
p<0.05, Dunn’s multiple comparison test) at p95 relative to vehicle-treatedmice (Fig 3C; right
panel). However, BNN27 (50 mg/kg) had no effect on PaGE task (p>0.05, Dunn’s multiple com-
parison test) relative to vehicle-treated female Tgmice at p95. Additionally, there was no change
in performance in the PaGE task in female Tg mice treated with BNN27 10 mg/kg or 50 mg/kg
at any other time point tested (p>0.05, Kruskal-Wallis test) (Fig 3C; right panel).
cultured with iAstrocytes from control untreated (control), SOD1 210 untreated (untreated), SOD1 210
Riluzole (Riluzole), and SOD1 210 BNN27 (BNN27). Scale bar = 20μM. c) Oxidative stress levels were
significantly increased in iAstrocytes from 2 ALS patients containing a SOD1 mutation (Patient 1/SOD1 91
and Patient 2/SOD1 210; light grey) compared to those from 2 control patients (white) (p<0.0001, Tukey’s
test). BNN27 treatment (red) produced a significant decrease in oxidative stress levels from SOD1
iAstrocytes relative to untreated cells (p<0.001, Tukey’s test). Scale bar = 10μM. Experiments were
performed in triplicate (a, c) and quadruplicate (b). Data are presented as mean ± SEMs. ** p<0.01,
***p<0.001, ****p<0.0001.
doi:10.1371/journal.pone.0164103.g001
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Motor coordination was assessed using the rotarod test. Similar to previous findings [52, 53,
63, 65], Tg vehicle-treatedmale mice demonstrated a decrease in the time spent on the rotarod
at p55 (Tg-vehicle: 78.8 sec,Wt-vehicle: 180.0 sec; p = 0.0089, Mann-Whitney U test), p95 (Tg-
vehicle: 17.2 sec,Wt-vehicle: 180.0 sec; p = 0.0192, Mann-Whitney U test), and p135 (Tg-vehi-
cle: 0.5 sec,Wt-vehicle: 180.0 sec; p = 0.0152, Mann-Whitney U test) relative to Wt vehicle-
treated male mice (Fig 3B; left panel). BNN27 did not alter rotarod performance in Tg male
mice treated with either BNN27 10 mg/kg or 50 mg/kg compared to vehicle treatment at any
time point assessed (p>0.05, Kruskal-Wallis test) (Fig 3B; right panel). Female Tg vehicle-
treated mice also demonstrated a decrease in the time spent on the rotarod at p55 (Tg-vehicle:
180.0 sec,Wt-vehicle: 180.0 sec; p = 0.0379, Mann-Whitney U test), p95 (Tg-vehicle: 22.3 sec,
WT-vehicle: 180.0 sec; p = 0.0026, Mann-Whitney U test), and p135 (Tg-vehicle: 2.4 sec,WT-
vehicle: 180.0 sec; p = 0.0002, Mann-Whitney U test) relative to Wt vehicle-treated female
Fig 2. Effect of BNN27 treatment on body weight and neurological score in male and female mice. Tg
vehicle-treated mice (males and females combined) exhibited a significant decrease in percent weight
relative to baseline levels (a, left) at p105 (p = 0.0188, Mann-Whitney U test), p115 (p = 0.0025, Mann-
Whitney U test), p125 (p<0.0001, Mann-Whitney U test), p135 (p<0.0001, Mann-Whitney U test), and p145
(p<0.0001, Mann-Whitney U test) compared to Wt vehicle-treated mice. Tg vehicle-treated mice also
exhibited an increase in neurological score (b, left) at p95 (p = 0.0003, Mann-Whitney U test), p105
(p = 0.0036, Mann-Whitney U test), p115 (p = 0.0012, Mann-Whitney U test), p125 (p<0.0001, Mann-
Whitney U test), p135 (p<0.0001, Mann-Whitney U test), and p145 (p<0.0001, Mann-Whitney U test) relative
to Wt vehicle-treated mice. There was no significant effect of BNN27 (10 mg/kg or 50 mg/kg) treatment on
body weight or neurological score compared to vehicle treatment in Tg mice (p>0.05, Kruskal-Wallis test).
Wt-vehicle (n = 20; grey), Tg-vehicle (n = 19; grey), Tg-BNN27 10 mg/kg (n = 20; black), Tg-BNN27 50 mg/kg
(n = 18; red). Data are presented as median ± interquartile ranges. * p<0.05, ** p<0.01, ***p<0.001.
doi:10.1371/journal.pone.0164103.g002
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mice (Fig 3D; left panel). In contrast to the male findings, BNN27 treatment yielded an overall
effect on rotarod performance (p = 0.0054, Kruskal-Wallis test) in females. Specifically,
BNN27 10 mg/kg treatment in Tg female mice increased the time spent on rotarod (Tg-10 mg/
kg: 180.0 sec, Tg-vehicle: 22.3 sec; p<0.01, Dunn’s multiple comparison test) at p95 relative to
vehicle-treated Tg female mice (Fig 3D; right panel). However, BNN27 (50 mg/kg) had no
effect on rotarod performance (p>0.05, Dunn’s multiple comparison test) relative to vehicle-
treated female Tg mice at p95. Additionally, there was no change in rotarod performance in
female Tg mice treated with 10 mg/kg or 50 mg/kg BNN27 at any other time point tested
(p>0.05, Kruskal-Wallis test) (Fig 3D; right panel).
In addition to the PaGE and rotarod tests, we also performed gait assessment to determine
the effects of BNN27 treatment on stride length and width. In agreement with previous studies
[49, 63, 64, 66], male Tg vehicle-treatedmice demonstrated shortened stride length relative to
Wt vehicle-treatedmales only at p115 (Tg-vehicle: 5.5 cm,Wt-vehicle: 7.3 cm; p = 0.0136,
Mann-Whitney U test) but not at any other time point tested (p>0.05, Mann-Whitney U test)
(Fig 4A; left panel). Moreover, stride width was decreased in Tg vehicle-treatedmales com-
pared toWt vehicle-treated males at p95 (Tg-vehicle: 1.8 cm,Wt-vehicle: 2.0 cm; p = 0.0202,
Mann-Whitney U test) but not at any other time point tested (p>0.05, Mann-Whitney U test)
(Fig 4B; left panel). There was no effect of BNN27 treatment (10 mg/kg and 50 mg/kg doses)
on either stride length or width in Tg males (p>0.05, Kruskal-Wallis test) (Fig 4A and 4B; right
panel). Female Tg vehicle-treated mice exhibited a decrease in stride length at p95 (Tg-vehicle:
6.2 cm,Wt-vehicle: 6.7 cm; p = 0.0155, Mann-Whitney U test), p115 (Tg-vehicle: 5.7 cm,Wt-
vehicle: 7.1 cm; p = 0.0024, Mann-Whitney U test), and p135 (Tg-vehicle: 4.1 cm,Wt-vehicle:
6.9 cm; p = 0.0010, Mann-Whitney U test) compared to Wt vehicle-treatedmice (Fig 4C; left
panel). However, stride width was not significantly altered in Tg vehicle-treated females rela-
tive to Wt vehicle-treated females (p>0.05, Mann-Whitney U test) (Fig 4D; left panel). Similar
to the males, there was no change in stride length or width in Tg female mice treated with
BNN27 10 mg/kg or 50 mg/kg (p>0.05, Kruskal-Wallis test) compared to the vehicle treated
group (Fig 4C and 4D; right panel).
The effect of BNN27 treatment on the onset of motor symptoms and survival was also
assessed. BNN27 10 mg/kg and 50 mg/kg treatment did not significantly alter the age of paresis
onset (onset of motor symptoms) (p>0.05, Kruskal-Wallis test) or survival (p>0.05, Kruskal-
Wallis test) in male and female Tg mice (Fig 5A and 5B). However, females treated with
BNN27 10 mg/kg exhibited a trend towards an increase in the age of paresis onset (Tg-10 mg/
kg: 97 days, Tg-vehicle: 84 days; p = 0.0523, Mann-Whitney U test) relative to vehicle treat-
ment in Tg female mice (Fig 5B, left panel).
Fig 3. Effect of BNN27 treatment on paw grip endurance (PaGE) and rotarod in male and female mice.
Male Tg vehicle-treated mice demonstrated a significant decrease in time spent on the PaGE test (a, left) at
p95 (p = 0.0023, Mann-Whitney U test), p115 (p = 0.0003, Mann-Whitney U test), and p135 (p = 0.0385,
Mann-Whitney U test) and the rotarod test (b, left) at p55 (p = 0.0089, Mann-Whitney U test), p95
(p = 0.0192, Mann-Whitney U test), and p135 (p = 0.0152, Mann-Whitney U test) relative to Wt vehicle-
treated mice. Female Tg vehicle-treated mice demonstrated a decrease in time spent on the PaGE test (c,
left) at p95 (p = 0.0128, Mann-Whitney U test), p115 (p<0.0001, Mann-Whitney U test), and p135 (p<0.0001,
Mann-Whitney U test) and the rotarod test (d, left) at p55 (p = 0.0379, Mann-Whitney U test), p95
(p = 0.0026, Mann-Whitney U test), and p135 (p = 0.0002, Mann-Whitney U test) relative to Wt vehicle-
treated mice. In Tg female mice, BNN27 10 mg/kg treatment significantly increased the time spent on the
PaGE (c, right) (p<0.05, Dunn’s multiple comparison test) and rotarod (d, right) (p<0.01, Dunn’s multiple
comparison test) tests compared to vehicle treatment at p95. Wt-vehicle (male: n = 10, female: n = 9; grey),
Tg-vehicle (male: n = 11, female: n = 11; grey), Tg-BNN27 10 mg/kg (male: n = 9, female: n = 9; black), Tg-
BNN27 50 mg/kg (male: n = 9, female: n = 9; red). Data are presented as median ± interquartile ranges. *
p<0.05, ** p<0.01, ***p<0.001, ****p<0.0001.
doi:10.1371/journal.pone.0164103.g003
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In addition to behavioral analyses, we also assessed the effects of BNN27 treatment on lower
motor neuron survival and NMJ integrity. As expected [49, 64, 65], there was a significant
decrease in relative motor neuron number in the lumbar spinal cord of Tg vehicle-treatedmice
compared toWt vehicle-treatedmice in both males (Tg-vehicle: 0.69, Wt-vehicle: 1.00;
p = 0.0095, Mann-Whitney U test) and females (Tg-vehicle: 0.59, Wt-vehicle: 1.00; p = 0.0042,
Mann-Whitney U test) (Fig 6). BNN27 treatment did not alter motor neuron survival in male
Fig 4. Effect of BNN27 treatment on stride length and width in male and female mice. Male Tg vehicle-
treated mice exhibited a decrease in stride length (a, left) at p115 (p = 0.0136, Mann-Whitney U test) and stride
width (b, left) at p95 (p = 0.0202, Mann-Whitney U test) relative to Wt vehicle-treated mice. Female Tg vehicle-
treated mice showed a decrease in stride length (c, left) at p95 (p = 0.0155, Mann-Whitney U test), p115
(p = 0.0024, Mann-Whitney U test), and p135 (p = 0.0010, Mann-Whitney U test) but no change in stride width
(d, left) (p>0.05, Mann-Whitney U test) compared to Wt vehicle-treated mice. There was no significant effect of
BNN27 treatment (10 mg/kg or 50 mg/kg) on stride length or width in either male or female Tg mice compared
to vehicle treatment (p>0.05, Kruskal-Wallis test) (a-d, right). Wt-vehicle (male: n = 10, female: n = 9; grey), Tg-
vehicle (male: n = 8, female: n = 11; grey), Tg-BNN27 10 mg/kg (male: n = 9, female: n = 9; black), Tg-BNN27
50 mg/kg (male: n = 9, female: n = 9; red). Data are presented as median ± interquartile ranges. * p<0.05, **
p<0.01, ***p<0.001.
doi:10.1371/journal.pone.0164103.g004
Fig 5. Effect of BNN27 treatment on paresis onset and survival in male and female mice. There was
no significant effect of BNN27 (10 mg/kg or 50 mg/kg) treatment on paresis onset or survival compared to
vehicle treatment in either male (p>0.05, Kruskal-Wallis test) or female (p>0.05, Kruskal-Wallis test) Tg
mice. However, BNN27 10mg/kg treatment in Tg female mice produced a trend (p = 0.0523, Mann-
Whitney U test) towards an increase in the age of paresis onset relative to Tg vehicle-treated female (b,
left). Tg-vehicle (male: n = 8, female: n = 11; grey), Tg-BNN27 10 mg/kg (male: n = 10, female: n = 10;
black), Tg-BNN27 50 mg/kg (male: n = 9, female: n = 9; red). Data are presented as percent values.
doi:10.1371/journal.pone.0164103.g005
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or female Tg mice at 10 mg/kg (p>0.05, Mann-Whitney U test) or 50 mg/kg (p>0.05, Mann-
WhitneyU test) compared to vehicle treated mice (Fig 6). Additionally, in agreement with pre-
vious findings [68–70], Tg vehicle-treated mice exhibited significant NMJ denervation as indi-
cated by a decrease in the overlap of presynaptic (vesicular acetylcholine transporter;VAChT)
and postsynaptic (α-bungarotoxin) markers in the tibialis anterior muscle in both males (Tg-
vehicle: 21.50, Wt-vehicle: 76.00; p = 0.0005, Mann-Whitney U test) and females (Tg-vehicle:
26.0, Wt-vehicle: 80.0; p = 0.0018, Mann-Whitney U test) relative to Wt vehicle-treatedmice
(Fig 7). There was no significant effect of BNN27 treatment (10 mg/kg or 50 mg/kg) on NMJ
denervation in both male (p>0.05, Mann-Whitney U test) and female (p>0.05, Mann-Whit-
neyU test) mice (Fig 7).
Fig 6. Effect of BNN27 treatment on motor neuron survival in male and female mice. There was
no change in motor neuron counts in a) male and b) female mice following BNN27 treatment. Top,
representative H&E stained longitudinal sections (10μM) of lumbar spinal cord from Wt vehicle-treated
mice and Tg mice treated with vehicle, BNN27 10 mg/kg, or BNN27 50 mg/kg. Arrows indicate motor
neurons; scale bar = 150μM. Bottom, quantification of motor neuron counts from Tg mice treated with
vehicle (male: n = 7, female: n = 11; grey), BNN27 10 mg/kg (male: n = 8, female: n = 10; black), and
BNN27 50 mg/kg (male: n = 9, female: n = 12; red) normalized to Wt vehicle-treated mice (male: n = 12,
female: n = 9; white). Tg vehicle-treated mice showed a decrease in the relative motor neuron number
compared to Wt vehicle-treated mice in both males (a; p = 0.0095, Mann-Whitney U test) and females (b;
p = 0.0042, Mann-Whitney U test). BNN27 treatment (10 mg/kg or 50 mg/kg) had no effect on motor
neuron counts in male (a; p>0.05, Kruskal-Wallis test) or female (b; p>0.05, Kruskal-Wallis test) mice.
Data are presented as median and 10-90th percentiles. ** p<0.01.
doi:10.1371/journal.pone.0164103.g006
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Upon termination of the behavioral and neuropathological analyses, we assayed the bio-
availability of BNN27 in post-mortem tissue. BNN27 was not detected in post-mortem brains
or spinal cords of treated mice (S2 Fig), in agreement with recent data from our consortium
demonstrating that BNN27 is rapidly metabolized in mouse compared to human hepatocytes
[71]. Together, these findings demonstrated that BNN27 does not significantly alter the disease
onset or progression in the G93A SOD1 mouse model of ALS. However, the rapid decay
Fig 7. Effect of BNN27 treatment on neuromuscular junction integrity in male and female mice. There
was no change in neuromuscular junction (NMJ) integrity in a) male and b) female mice following BNN27
treatment. Top, representative tibialis anterior sections (20μM) from Wt vehicle-treated mice and Tg mice
treated with vehicle, BNN27 10 mg/kg or 50 mg/kg. Sections were stained for α-Bungarotoxin (left: TMR-α-
Bungarotoxin 1:750; red) and the vesicular acetylcholine transporter (middle: VAChT 1:10,000; green). Overlay
images (right) show overlap of α-Bungarotoxin and VAChT. Scale bar = 20μM. Bottom, quantification of the
percent overlay between α-Bungarotoxin and VAChT from Tg mice treated with vehicle (male: n = 8, female:
n = 11; grey), BNN27 10 mg/kg (male: n = 10, female: n = 10; black) or BNN27 50 mg/kg (male: n = 11, female:
n = 13; red) normalized to Wt vehicle-treated mice (male: n = 10, female: n = 9; white). Tg vehicle-treated mice
showed a decrease in the relative overlap compared to Wt vehicle-treated males (p = 0.0005, Mann-Whitney U
test) and females (p = 0.0018, Mann-Whitney U test). Data are presented as median and 10-90th percentiles.
** p<0.01, *** p<0.001.
doi:10.1371/journal.pone.0164103.g007
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kinetics of BNN27 in the mouse along with the neuroprotective effects of BNN27 in iAstro-
cyte-mouseMN co-cultures suggest that human-derived cell lines or larger animals may pro-
vide a more appropriate model for testingMNT efficacy in ALS.
Discussion
In the current study, the neuroprotective effects of the MNT BNN27, a novel DHEA derivative,
were assessed in mouse motor neurons co-culturedwith human astrocytes from ALS patients
with a SOD1 mutation and in the G93A SOD1mouse model of ALS. Our findings demonstrate
that in vitro BNN27 (10 μM) attenuated loss of motor neurons co-culturedwith human SOD1
iAstrocytes via the reduction of oxidative stress. Additionally, in the G93A SOD1mouse,
BNN27 (10 mg/kg) treatment attenuated motor behavioral impairment in the PaGE and
rotarod tasks at p95 in female but not male mice. However, BNN27 (10 mg/kg and 50 mg/kg)
treatment did not affect body weight, neurological score, gait, the age of onset of paresis or sur-
vival in male or female mice. In addition, lumbar spinal cord motor neuron number and tibialis
anterior NMJ integrity were not altered following BNN27 treatment (10 mg/kg and 50 mg/kg)
in male or female mice. Moreover, our results demonstrate that BNN27 was not detected in the
brain or spinal cord of treated mice, in agreement with in vitro experiments from our consor-
tium illustrating that BNN27 was quickly metabolized by mouse hepatocytes [71]. Together,
these data demonstrate that BNN27 treatment failed to produce significant neuroprotective
effects in the G93A SOD1 mice likely due to its rapid rate of metabolism in mice.
In this study, we demonstrated that BNN27 reducedMN cell loss in in vitro co-cultures at
least in part via a decrease in oxidative stress. Oxidative stress has been shown to play a major
role in several neurodegenerative diseases, including ALS. Previous work from our group dem-
onstrated that overexpression of mutant SOD1 in NSC34 cells resulted in a suppression of the
cellular antioxidant response [72], thus identifying oxidative stress as one of the toxic mecha-
nisms leading to MN cell death. Our current findings are consistent with previous data demon-
strating that therapeutic approaches that enhance the anti-oxidant cellular response in
astrocytes are beneficial and protective in the G93A SOD1mouse [73].
In the current study, we found that BNN27 treatment (10 mg/kg) significantly improved
performance in the PaGE and rotarod tasks in female mice only at p95 (Fig 4C and 4D, right
panel). These data suggest a sex-specific effect of drug treatment in female G93A SOD1 mice,
which has not been previously reported. Prior studies have described a more significant ther-
apeutic improvement in female relative to male G93A SOD1 mice [74, 75]. However, previ-
ous reports describing sex-specific effects of therapeutic treatment have been limited to male
G93A SOD1 mice only [76–83]. In addition, disparate disease courses have been described in
male and female G93A SOD1 mice even when age- and litter-matching occurred. Specifi-
cally, female G93A SOD1 mice exhibit prolonged survival compared to male cohorts [58,
59], in agreement with the findings from our present study (S1 Fig). Moreover, when litter-
matching is employed, there is decreased noise within a female-only cohort, compared to a
male-only cohort [59]. An alternative explanation for these findings is the possible interac-
tion of BNN27 with the estrogen receptor (ER). Although previous in vitro data demonstrate
that MNTs do not activate hormone receptors at nanomolar concentrations [46], in this
study, BNN27 was administered continuously via slow release pellets at 10 and 50 mg/kg,
doses, which may lead to the activation of ER or other hormone receptors. Together these
sex-specific differences may contribute to the significant behavioral improvement seen in
female but not male G93A SOD1 mice in the current study.
Our findings illustrate that the G93A SOD1mutant mice exhibit a high degree of behavioral
variability, even within age-matched and litter-matched sample groups, which agrees with
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previous findings [58, 59]. Therefore, in accordance with published guidelines [59, 84] we
aimed for large samples sizes (~24 gender-balancedmice per experimental group) for this
study but ended up fewer mice than initially anticipated (18–20 gender-balancedmice per
experimental group) due to several factors. Severalmice were omitted from the study due to
pellet implantation issues for the BNN27 50 mg/kg group. As expected, the 50 mg/kg pellets
were larger in size than the placebo or 10 mg/kg pellets. Therefore, the pellets partially or
completely fell out in some mice that were subsequently excluded from the study. Moreover, a
fewmice died during the study from issues unrelated to the drug treatment or the normal dis-
ease course in G93A SOD1 mice and were thus excluded from the study in accordance with the
recommended guidelines for this mouse line [57, 59]. Therefore, the reduced sample sizes
could in part explain the lack of effect of BNN27 treatment on Tg SOD1 mice and future stud-
ies with these compounds might benefit from a larger sample size.
The major confound in this study was the bioavailability and metabolism of BNN27. Mass-
spectrometry results demonstrated that BNN27 was not detected in post-mortem brain or spi-
nal cord tissue from BNN27 treated mice (S2 Fig). In contrast, BNN27 was detected in post-
mortemmouse brain tissue at 30 min following an acute i.p. injection of BNN27 (50 mg/kg)
[71]. The discrepancy between these data could be due to issues with the pellet formulation or
timing of drug administration with the implanted pellets relative to when tissue was collected.
Additionally, at 30 min following an i.p. injection of BNN27 (50 mg/kg), two hydroxylated
metabolites of BNN27 were also present in post-mortem brain tissue [71]. However, the func-
tion of these metabolites is not yet known. It is possible that these BNN27 metabolites could
bind to TrkA receptors and activate anti-apoptotic downstream signaling cascades similar to
NGF or DHEA. However, the modest behavioral improvements seen in this study (only in
females at p95) suggest that these metabolites are not activating the same proposed down-
stream signaling cascades, of DHEA-like compounds, to exert neuroprotective effects. Regard-
less, further in vitro studies are warranted to determine the function and downstream effects of
these hydroxylated metabolites of BNN27.
To assess the metabolic profile of BNN27, our consortium performed in vitro studies with
human and mouse hepatocytes [71]. The same two hydroxylated BNN27 metabolites, detected
after i.p. injection, were found following BNN27 incubation with both mouse and human
hepatocytes [71]. However, the half-life of BNN27 was markedly shorter in experiments using
mouse hepatocytes relative to human hepatocytes [71]. These data suggest that BNN27 may be
largely metabolized before entering the CNS in mice and explain the absence of BNN27 in the
brain and spinal cord of treated mice. The longer half-life of BNN27 in human hepatocytes
suggests that BNN27 may provide neuroprotective effects in human ALS cell models. However,
this area requires further exploration.
Human induced pluripotent stem (iPS) cells and induced neural progenitor cells (iNPCs)
from ALS patients have been used to model disease phenotypes and assess drug outcomes [48,
85–89]. Specifically, human ALS astrocyte-mousemotor neuron co-cultures have been previ-
ously employed to test potential therapeutic approaches [60, 90] similar to the approach taken
in our current study (Fig 1). Therefore, future studies building on our current findings in
patient-derived cells (Fig 1) could provide a more appropriate model for testing the potential
efficacyof these novel DHEA derivatives. Moreover, future BNN27 metabolism studies in
hepatocytes from other large animals (e.g. dogs, pigs) could provide important information
regarding the metabolism profile of BNN27. In conclusion, our study was not able to assess the
neuroprotective efficacy of BNN27 in vivo as the parent MNT was not detected in the CNS.
Thus, more extensive and additional studies in other ALS models are warranted in order to jus-
tify the potential use of BNN27 as a novel treatment in human ALS patients.
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Supporting Information
S1 Fig. Survival in male and female Tg SOD1 mice. Female Tg vehicle-treatedmice exhibited
prolonged survival (female: 142 d, n = 10; male: 128 d, n = 8; p = 0.0190, Mann-Whitney U
test) relative to male Tg vehicle-treatedmice.  p<0.05.
(PDF)
S2 Fig. BNN27 levels in post-mortembrain and spinal cord tissue from treatedmice.
BNN27 was not present in post-mortem a) brain or b) spinal cord following chronic pellet
implantation. A representative LC-MS/MS graph showing that BNN27 levels were undetect-
able (below the limit of quantification) in post-mortem a) brain and b) spinal cord from pellet
(50 mg/kg) implanted mice.
(PDF)
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